Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.62 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.62 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.49 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 3/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL664284 | 0.88 | NPC1 (0.79) | NPC1RAB9AAKR1C3AKR1C1DGAT1 | |
| SCHEMBL2511695 | 0.88 | NPC1 (0.79) | NPC1RAB9AAKR1C3AKR1C1DGAT1 | |
| SCHEMBL3516198 | 0.88 | NPC1 (0.79) | NPC1RAB9AAKR1C3AKR1C1DGAT1 | |
| SCHEMBL4449225 | 0.86 | NPC1 (0.76) | NPC1RAB9AAKR1C3AKR1C1DGAT1 | |
| SCHEMBL27478716 | 0.86 | NPC1 (0.76) | NPC1RAB9AAKR1C3AKR1C1DGAT1 | |
| SCHEMBL4444928 | 0.86 | NPC1 (0.76) | NPC1RAB9AAKR1C3AKR1C1DGAT1 | |
| Hydrochloric Acid SCHEMBL10892943 | 0.86 | NPC1 (0.76) | NPC1RAB9AAKR1C3AKR1C1DGAT1 | |
| Biphenyl SCHEMBL7611759 | 0.86 | RAB9A (0.74) | NPC1RAB9AAKR1C3AKR1C1MEN1 | |
| Biphenyl SCHEMBL11881576 | 0.86 | RAB9A (0.74) | NPC1RAB9AAKR1C3AKR1C1MEN1 | |
| SCHEMBL3302853 | 0.84 | NPC1 (0.71) | NPC1RAB9AKDM1AMAOBDEGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700615-B2 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1576110-A4 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | AVOLIX PHARMACEUTICALS (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060128742-A1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| US-7012100-B1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1576110-A2 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | Avolix Pharmaceuticals (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2003102153-A2 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | AVOLIX PHARMACEUTICALS (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128742-A1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | MKI67, DCX, NUDC | NPC1 1204/4885RAB9A 714/4885AKR1C3 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.